These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 32238056)

  • 1. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma.
    Johanns TM; Garfinkle EAR; Miller KE; Livingstone AJ; Roberts KF; Rao Venkata LP; Dowling JL; Chicoine MR; Dacey RG; Zipfel GJ; Kim AH; Mardis ER; Dunn GP
    Clin Cancer Res; 2024 Jul; 30(13):2729-2742. PubMed ID: 38639919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising vaccines for treating glioblastoma.
    Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
    Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
    Supabphol S; Li L; Goedegebuure SP; Gillanders WE
    Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized cancer neoantigen vaccines come of age.
    Chu Y; Liu Q; Wei J; Liu B
    Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
    Latzer P; Zelba H; Battke F; Reinhardt A; Shao B; Bartsch O; Rabsteyn A; Harter J; Schulze M; Okech T; Golf A; Kyzirakos-Feger C; Kayser S; Pieper N; Feldhahn M; Wünsche J; Seitz C; Hadaschik D; Garbe C; Hauser TK; la Fougère C; Biskup D; Brooke D; Parker D; Martens UM; Illerhaus G; Blumenthal DT; Merrell R; Lorenzo LS; Hidvégi M; de Robles P; Kebir S; Li WW; Li VW; Williams M; Miller AM; Kesari S; Castro M; Desjardins A; Ashley DM; Friedman HS; Wen PY; Neil EC; Iwamoto FM; Sipos B; Geletneky K; Zender L; Glas M; Reardon DA; Biskup S
    Nat Commun; 2024 Aug; 15(1):6870. PubMed ID: 39127809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.
    Wu DW; Jia SP; Xing SJ; Ma HL; Wang X; Tang QY; Li ZW; Wu Q; Bai M; Zhang XY; Fu XF; Jia MM; Tang Y; Chen L; Li N
    Clin Exp Med; 2024 Sep; 24(1):229. PubMed ID: 39325256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.
    Johanns TM; Dunn GP
    Cancer J; 2017; 23(2):125-130. PubMed ID: 28410300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.